USA flag logo/image

An Official Website of the United States Government

ENDOGENOUS ANTI-INFLAMMATORY PROTEIN: BIOLOGICAL TESTING

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
2945
Program Year/Program:
1986 / SBIR
Agency Tracking Number:
2945
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
California Biotechnology, Inc.
2450 Bayshore Parkway Mountain View, CA 94043
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1986
Title: ENDOGENOUS ANTI-INFLAMMATORY PROTEIN: BIOLOGICAL TESTING
Agency: HHS
Contract: N/A
Award Amount: $500,000.00
 

Abstract:

INFLAMMATORY DISORDERS ACCOUNT FOR A SIGNIFICANT PERCENTAGE OF DEBILITATING DISEASES. IT IS NOW APPARENT THAT CENTRAL TO THE THERAPEUTIC CONTROL OF THE INFLAMMATORY REACTION IS THE REGULATION OF THE PHOSPHOLIPID METABOLITES, THE EICOSANOIDS. IN MOST TISSUES THE SYNTHESIS OF THE EICOSANOIDS IS LIMITED BY THE AVAILABILITY OF ARACHIDONIC ACID (AA) WHICH IS FIRST LIBERATED FROM MEMBRANE PHOSPHOLIPIDS BY THE ACTIVITY OF PHOSPHOLIPASE A2 (PLA2). THE GOAL OF THE PROPOSED WORK IS THEREFORE TO TEST THE BIOLOGICAL EFFICACY OF AN ENDOGENOUS INHIBITOR OF PLA2 ISOLATED FROM HUMAN SOURCES. PHASE I IS DIRECTED TOWARDS: 1.DETERMINING THE HALF-LIFE OF THE INHIBITOR WHEN INJECTED I.V. INTO EXPERIMENTAL ANIMALS; 2.DETERMINING IF THE INHIBITOR MAY DISRUPT THE PROSTACYCLIN/THROMBOXANE A2 BALANCE; 3.DETERMINING IF THE INHIBITOR IS EFFECTIVE AS AN ANTI-INFLAMMATORY THERAPEUTIC IN ACUTE MODELS OF INFLAMMATION BY ASSESSING ITS EFFECT ON RAT HINDPAW EDEMA, PLEURAL CAVITY INFLAMMATION, AND ADJUVANT-INDUCED POSITIVE RESULTS OF THE PHASE I RESEARCH WILL LEAD TO THE DEVELOPMENT IN PHASE II OF AN ACTIVE, SYNTHETIC FRAGMENT OF THE PLA2 INHIBITOR AND TO ITS DELIVERY USING AN ADJUVANT-DIRECTED NASAL DELIVERY SYSTEM. THE RESULTS COULD LEAD TO THE DEVELOPMENT OF AN ANTI-INFLAMMATORY THERAPEUTIC WHICH DOES NOT CARRY THE SIDE EFFECTS AND TOXICITY OF EXISTING NONENDOGENOUS ANTI-INFLAMMATORY DRUGS AND COULD BE USED TO TREAT ARTHRITIS, SYSTEMIC LUPUS, PSORIASIS, AND POSSIBLY ATHEROSCLEROSIS.

Principal Investigator:

Lorin K. Johnson
Principal Investigator
4159661550

Business Contact:

Small Business Information at Submission:

California Biotechnology Inc.
2450 Bayshore Frontage Road Mountain View, CA 94043

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No